European Research Initiative on CLL

ERIC | Publications

Publications

Rosenquist R, Rosenwald A, Du MQ, Gaidano G, Groenen P, Wotherspoon A, Ghia P, Gaulard P, Campo E, Stamatopoulos K; European Research Initiative on CLL (ERIC) and the European Association for Haematopathology (EAHP).

Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond

  • Haematologica. 2016 Sep;101(9):1002-9. doi: 10.3324/haematol.2015.134510. Review

..............................................................................................................................................................................................................................................................................................................

Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J, Stalika E, Pedersen LB, Malcikova J, Agathangelidis A, Davis Z, Mansouri L, Scarfò L, Boudjoghra M, Navarro A, Muggen AF, Yan XJ, Nguyen-Khac F, Larrayoz M, Panagiotidis P, Chiorazzi N, Niemann CU, Belessi C, Campo E, Strefford JC, Langerak AW, Oscier D, Gaidano G, Pospisilova S, Davi F, Ghia P, Stamatopoulos K, Rosenquist R; ERIC, the European Research Initiative on CLL.

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors

  • Haematologica 2016 Aug;101(8):959-67

...............................................................................................................................................................................................................................................................................................................

Pospisilova S, Sutton L, Malcikova J, Tausch E, Rossi D, Montserrat E, Moreno C, Stamatopoulos K, Gaidano G, Rosenquist R, Ghia P, on behalf of the European Research Initiative on CLL (ERIC)

Innovation in CLL prognostication – how far beyond TP53 gene analysis are we?

  • Haematologica 2016 Mar;101(3):263-5

..................................................................................................................................................................................................................................................................................................................................................................................................................

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P

A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study.

..................................................................................................................................................................................................................................................................................................................................................................................................................

C Moreno, M Montillo, P Panayiotidis, M Dimou, A Bloor, J Dupuis, A Schuh, S Norin, C Geisler, P Hillmen, M Doubek, M Trněný, P Obrtlikova, L Laurenti, S Stilgenbauer, L Smolej, P Ghia, F Cymbalista, U Jaeger, K Stamatopoulos, N Stavroyianni, P Carrington, H Zouabi, V Leblond, J C Gomez-Garcia, M Rubio, R Marasca, G Musuraca, L Rigacci, L Farina, R Paolini, S Pospisilova, E Kimby, C Bradley, E Montserrat

Ofatumumab In Poor-Prognosis Chronic Lymphocytic Leukemia: A Phase IV, Non-Interventional, Observational Study From The European Research Initiative On Chronic Lymphocytic Leukemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

P Baliakas, A Hadzidimitriou, L-A Sutton, D Rossi, E Minga, N Villamor, M Larrayoz, J Kminkova, A Agathangelidis, Z Davis, E Tausch, E Stalika, B Kantorova, L Mansouri1, L Scarfò, D Cortese, V Navrkalova, M J J Rose-Zerilli, K E Smedby, G Juliusson, A Anagnostopoulos, A M Makris, A Navarro, J Delgado, D Oscier, C Belessi, S Stilgenbauer, P Ghia, S Pospisilova, G Gaidano, E Campo, J C Strefford K Stamatopoulos and R Rosenquist, on behalf of the European Research Initiative on CLL (ERIC)

Recurrent mutations refine prognosis in chronic lymphocytic leukemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Dreger P, Montserrat E; European Society for Blood and Marrow Transplantation (EBMT); European Research Initiative on CLL (ERIC). Curr Hematol Malig Rep. 2015 Mar;10(1):59-64. doi: 10.1007/s11899-014-0242-1. Review.

Abstract

Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?

..................................................................................................................................................................................................................................................................................................................................................................................................................

Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E, European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT).

Managing high-risk chronic lymphocytic leukemia during transition to a new treatment era: stem cell transplantation or novel agents?

..................................................................................................................................................................................................................................................................................................................................................................................................................

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC).

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis

..................................................................................................................................................................................................................................................................................................................................................................................................................

Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach

..................................................................................................................................................................................................................................................................................................................................................................................................................

Te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC)

Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

..................................................................................................................................................................................................................................................................................................................................................................................................................

Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T
ERIC recommendations on TP53 mutation analysis in Chronic Lymphocytic Leukemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Langerak AW, Davi F, Ghia P, Hadzidimitriou A, Murray F, Potter KN, Rosenquist R, Stamatopoulos K, Belessi C
Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases

..................................................................................................................................................................................................................................................................................................................................................................................................................

T Zenz, D Vollmer, M Trbusek, J Smardova, A Benner, T Soussi, H Helfrich, M Heuberger, P Hoth, M Fuge, T Denzel, S Häbe, J Malcikova, P Kuglik, S Truong, N Patten, L Wu, D Oscier, R Ibbotson, A Gardiner, I Tracy, K Lin, A Pettitt, S Pospisilova, J Mayer, M Hallek, H Döhner and S Stilgenbauer for the European Research Initiative on CLL (ERIC)
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

P53 function project Coordinators: A. Kater (Amsterdam, The Netherlands); S. Stilgenbauer (Ulm, Germany)
Publications: Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia G. Doreen te Raa, J Malcikova, S Pospisilova, M Trbusek, Mark Mraz, M Le Garff-Tavernier, H Merle-Béral, K Lin, A Pettitt, O Merkel, T Stankovic, M. van Oers, E Eldering, S Stilgenbauer, T Zenz, A Kater, European Research initiative on CLL (ERIC) » more ..................................................................................................................................................................................................................................................................................................................................................................................................................

Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S.
From pathogenesis to treatment of chronic lymphocytic leukaemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Kostas Stamatopoulos, Paolo Ghia, Richard Rosenquist, Eds.
New Biological prognostic markers in CLL
WKHealth Books| 2010 ISBN: 978-88-7556-551-0

prognosticmarkerscover
This book is free to ERIC members!

..................................................................................................................................................................................................................................................................................................................................................................................................................

Michael Keating, Emili Montserrat, Eds.
Updates in chronic lymphocytic leukemia
Permanyer Publications | 2009 ISBN: 978-84-92620-25-8

updates-in-CLL_2009_cover_thumb
This book is free to ERIC members!

..................................................................................................................................................................................................................................................................................................................................................................................................................


Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S.
miR-34a as part of the resistance network in chronic lymphocytic leukemia
# Blood, 2009 Apr 16;113(16):3801-8

..................................................................................................................................................................................................................................................................................................................................................................................................................

Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M, Helfrich H, Mertens D, Dohner H, Stilgenbauer S
Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.

..................................................................................................................................................................................................................................................................................................................................................................................................................

Paolo Ghia, Richard Rosenquist, Frederic Davì, Eds.
Immunoglobulin gene analysis in Chronic Lymphocytic Leukemia
WKHealth Books | 2008 ISBN: 978-88-7556-377-6

ig_analysis_book_cover_thumb
This book is free to ERIC members!

..................................................................................................................................................................................................................................................................................................................................................................................................................

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group NCI-WG) 1996 guidelines

..................................................................................................................................................................................................................................................................................................................................................................................................................

Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P on behalf of European Research Initiative on CLL (ERIC) and the CLL Research Consortium (http://cll.ucsd.edu/)
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

  • Leukemia, 2007 May;21(5):956-64 ..................................................................................................................................................................................................................................................................................................................................................................................................................

Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F, Davi F, Rosenquist R; European Research Initiative on CLL
ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Letestu R, Rawstron A, Ghia P, Villamor N, Boeckx N, Boettcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A, Langerak A, Le Garff-Tavernier M, Mockridge I, Morilla A, Padmore R, Rassenti L, Ritgen M, Shehata M, Smolewski P, Staib P, Ticchioni M, Walker C, Ajchenbaum-Cymbalista F, and On behalf of the ERIC (European Research Initiative in CLL) and the Leukemianet
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process

Este sitio web ha sido creado y es gestionado mediante la tecnología uniweb, desarrollada por intelligenia.

Web - Ingeniería y Diseño - intelligenia